Loading
  • Home
  • About
  • Technology
  • Pipeline
  • Careers
  • Investors & Media
  • Contact
  • Twitter
  • LinkedIn
  • Close Menu
  • Menu Menu

Pipeline

We are advancing our clinical-stage pipeline of differentiated treatments focused on chronic diseases with unmet need around the globe, including cardiovascular, metabolic and pulmonary conditions.

Program

Indication

Discovery

IND-enabling

Phase 1

Phase 2

Oral GLP-1R Franchise

GSBR-1290

GLP-1R

Type 2 Diabetes and Obesity

Phase 1

Next Gen GSBR

Dual GLP-1R / GIPR

Type 2 Diabetes and Obesity

Discovery

Oral APJR

ANPA-0073

APJR

Cardiopulmonary

Phase 1

Oral LPA1R

LTSE-2578

LPA1R

Idiopathic Pulmonary Fibrosis (IPF)

IND-enabling

Therapeutic Area Focus

Chronic diseases are rapidly increasing worldwide, escalating the demand for life-changing medicines. These conditions represent 73% of all deaths worldwide and 60% of the global burden of disease. At Structure, we are determined to transform these devastating figures with innovative, small molecule medicines.

417 Million

suffer from Type 2 Diabetes

46% increase  by 2045
90% of T2DM patients are overweight or obese

  • Diabetes

  • Obesity

  • NAFLD/NASH

150 Million

suffer from our cardiopulmonary disease areas of focus

>2x increase in incidence of pulmonary fibrosis over last 30 yrs
Mortality can occur within 3-5 yrs

  • Pulmonary Hypertension

  • Pulmonary Fibrosis

  • Heart Failure

Privacy Policy | Terms of Use 2023 Structure Therapeutics
Scroll to top